Depression study shows influence of patients' treatment expectancies

Semaglutide shows favorable safety profile in patients receiving clozapine
Published: (2025)

Psilocybin‐assisted therapy shows range of benefits in cancer patients
Published: (2025)

Olanzapine plus samidorphan shows long‐term safety in patients with schizophrenia
Published: (2025)

Study of young psychiatric patients shows potential preventive benefit of doxycycline
Published: (2026)

Trial shows safety of switch to xanomeline‐trospium combination in stable patients
Published: (2026)

Pharmacogenomic testing influenced prescribing in patients with depression
Published: (2025)

Patients with COPD show risk of worsening from gabapentinoids
Published: (2024)

LAI antipsychotics show effective results in comparative analysis
Published: (2024)

Esketamine's effects in combination with SSRI vs. SNRI show differences
Published: (2025)

Study shows improved schizophrenia negative symptoms with xanomeline‐trospium
Published: (2025)

LAI paliperidone shows favorable long‐term results in schizophrenia
Published: (2024)

Serotonin 4 receptor agonist shows promise in preventing depression
Published: (2024)

Xanomeline‐trospium combination shows strong results in schizophrenia trial
Published: (2024)

Review: Haloperidol, fluphenazine, clozapine show poor results on cognition
Published: (2024)

Ketamine outperforms ECT on cognitive function in patients with treatment‐resistant depression
Published: (2026)

Second Phase 3 trial shows benefit of xanomeline‐trospium in schizophrenia
Published: (2024)

Review shows cannabinoids have small effect on chronic pain symptoms
Published: (2026)

Anti‐inflammatory treatment could help improve symptoms in some patients with depression
Published: (2026)

Fast‐acting psychedelic shows antidepressant effects in Phase 2A trial
Published: (2025)

Cannabis laws may influence trends in prescribing of psychotropics
Published: (2024)

Pharmacological treatments for psychotic depression
by: Y. W. Francis Lam
Published: (2024)

Esketamine monotherapy efficacious in treatment‐resistant depression
Published: (2025)

Concurrent metformin improves adherence to SGA treatment
Published: (2026)

Oral formulation of ketamine effective for treatment‐resistant depression
Published: (2024)

Review questions sustained efficacy of esketamine in treatment‐resistant depression
Published: (2025)

Adding behavioral therapy does not enhance buprenorphine treatment of OUD
Published: (2025)

Ileus, pneumonia among most burdensome effects of clozapine treatment
Published: (2024)

Benefits of buprenorphine over methadone offset by lower treatment retention
Published: (2026)

Expert group calls for re‐establishing MAOIs in treatment protocols
Published: (2026)

Review finds VMAT‐2 inhibitors promising for treatment of psychosis
Published: (2024)

SSRI, SNRI augmentation of clozapine reduces relapse in treatment‐resistant schizophrenia
Published: (2025)

Meta‐analysis suggests risk of psychosis from stimulant treatment for ADHD
Published: (2025)

Study finds gabapentinoid treatment does not elevate risk of self‐harm
Published: (2025)

When both treatments unblinded, psychedelics not more effective than antidepressants
Published: (2026)

Combining MRI, clinical data has predictive value in sertraline treatment
Published: (2024)

Umbrella review finds several ADHD treatments efficacious in short term
Published: (2026)